Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
190 Leser
Artikel bewerten:
(0)

Velos Introduces Velos Volunteer - Compliant, Ethical and Efficient Subject Recruitment

FREMONT,Calif., March 21, 2012 /PRNewswire/ --Velos, Inc., the trusted leader in clinical research software, will introduce its Velos Volunteer web application at the American Medical Informatics Association (AMIA) 2012 Summit on Clinical Research Informatics in San Francisco, California on March 21 to 24. Velos Volunteer helps organizations enlist and manage future participants in clinical trials through a process-oriented, ethical, and compliant methodology.

"We are pleased to release Velos Volunteer to improve compliance and efficiency in the recruitment process for clinical trials and to support meaningful use of data from medical records," said John McIlwain, President of Velos.

Currently, most researchers, coordinators, and nurses maintain respondent contact information on paper, spreadsheets, and sundry databases. This inefficient process is often not fully compliant with existing rules and best practices for recruitment in clinical trials. For example, it is necessary to select volunteers fairly on a first-come, first-serve basis and eliminate bias. There is also an acute need for research sites to present recruitment capabilities and strategies to industry sponsors as well as evidence-based data measuring recruitment success and failure. Velos Volunteer provides metrics for enrollment and screening reporting to address these needs that are often otherwise not readily available. Ethical and compliant recruitment is also a great way to achieve meaningful use of medical records if supported by the proper systems.

"Velos Volunteer provides us with a sponsor-friendly recruitment dataset and uniform, audit-ready workflow throughout our entire recruiting process. We can load electronically large numbers of patients we identify as possible enrollment candidates from our clinical data repository and manage them through the same process," said Julie Eckstrand, Assistant Director - Clinical Support Services and Quality Management.

Velos Volunteer remedies these problems through a secure system that complies with institutional security, IRB and HIPAA requirements. The database and consent for storage of PHI is an IRB-approved protocol itself that is not limited to a specific study. System features include call tracking, script management, inclusion/exclusion criteria and response management, blacklisting, and messaging. The system also provides a platform to inform respondents of the risks and benefits on a one-on-one basis which facilitates adherence to good clinical practice. The system also incorporates intuitive workflow-based design to navigate based on the direction of conversation with respondents. In addition to addressing compliance and meaningful use needs, Velos Volunteer works the way recruiters work and reduces time spent performing redundant tasks.

About Velos - Velos is the trusted clinical trial management resource for investigators, sponsors, and academic leaders throughout the U.S. Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. System users are freed of redundant data entry and related time delays associated with most clinical research today. Velos integrates the clinical, administrative, and financial information needs of research management, with an emphasis on flexibility and workflow. Founded in 1996, Velos, Inc. is privately held with headquarters in Fremont, California. For more information, visit http://www.velos.com/

*This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.

SOURCE Velos, Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.